Remove Blood Clot Remove Stent Remove Strokes
article thumbnail

Abstract TP214: In-Silico versus In-Vitro Evaluation of a New Stent-Retriever Design: A Novel Approach to Pre-Clinical Device Development

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page ATP214-ATP214, February 1, 2024. In-silico evaluation (computer simulated analysis in a virtual stroke model) has the potential to test and optimize large number of stent-retriever design variations in a relatively time and cost-effective manner.

Stent 40
article thumbnail

Abstract 249: In?silico Versus In?Vitro Evaluation of a New Stent?Retriever Design: A Novel Approach to Pre?clinical Development

Stroke: Vascular and Interventional Neurology

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. In‐silico evaluation (computer simulated analysis in a virtual stroke model) has the potential to test and optimize large number of stent‐retriever design variations in a relatively time and cost‐effective manner.

Stent 40
article thumbnail

No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1, A Building Block of HDL Cholesterol

DAIC

milla1cf Sat, 04/06/2024 - 18:32 April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at the American College of Cardiology ’s Annual Scientific Session.

article thumbnail

The Texas Heart Institute Collaborates on Multi-institutional DOD Grant to Develop Novel Left Ventricular Assist Device

DAIC

As an alternative therapeutic option, LVAD heart pumps have been implanted to help patients with end-stage heart failure sustain blood circulation in the body. However, there are shortcomings associated with LVAD implantation: complications include infection, blood clotting (thrombosis), stroke and bleeding.

article thumbnail

Research Presented at ACC 2024 Found No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1

DAIC

The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at ACC.24, reduction in risk for death, heart attack or stroke compared with 5.2%

article thumbnail

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices 

Cardiometabolic Health Congress

February 2024 FDA Approvals: Innovations in Cardiovascular Interventions XACT Carotid Stent System (Approved: 02/07/2024) This approval expands the indications to be used during a Transcarotid Artery Revascularization (TCAR) procedure to prevent future strokes. The label includes a “black box” warning for CV risk due to blood clots.

article thumbnail

WELCOME TO THE PRIMARY BANK OF ASPIRIN

Dr. Sanjay Gupta

This is called the Primary Bank because it is only for those people who have never had a heart attack or a stroke but are looking to prevent one from happening by taking Aspirin daily. So if you have never had a cardiac event or a stroke, the Primary Bank of Aspirin is the bank that you need to know about.